Area of research
Oncology · Molecular Biology
Research interest
Research interests include Bone Metabolism and Diseases, Bone health and treatments, Pancreatic and Hepatic Oncology Research, and Diabetes Treatment and Management.
Corrigendum to “Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R” [Biomed. Pharmacother. 130 (2020) 110523]
Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women
Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats
Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).
Polymorphisms in the glucagon-like peptide-1 receptor gene and their interactions on the risk of osteoporosis in postmenopausal Chinese women
Aucubin Impeded Preosteoclast Fusion and Enhanced CD31hi EMCNhi Vessel Angiogenesis in Ovariectomized Mice
PGE2/EP4 skeleton interoception activity reduces vertebral endplate porosity and spinal pain with low-dose celecoxib
Parathyroid hormone attenuates osteoarthritis pain by remodeling subchondral bone in mice
TRPV1 Channel Activated by the PGE2/EP4 Pathway Mediates Spinal Hypersensitivity in a Mouse Model of Vertebral Endplate Degeneration
Curculigoside Ameliorates Bone Loss by Influencing Mesenchymal Stem Cell Fate in Aging Mice
Sensory nerves regulate mesenchymal stromal cell lineage commitment by tuning sympathetic tones
Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R
Analysis and Validation of Differentially Expressed MicroRNAs with their Target Genes Involved in GLP-1RA Facilitated Osteogenesis
IRS-1 targets TAZ to inhibit adipogenesis of rat bone marrow mesenchymal stem cells through PI3K-Akt and MEK-ERK pathways
Sal B targets TAZ to facilitate osteogenesis and reduce adipogenesis through MEK‐ERK pathway
Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system
Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study
RETRACTED ARTICLE: Association of the polymorphisms in <i>FOXO1</i> gene and diabetic nephropathy risk
Liraglutide Inhibits the Apoptosis of MC3T3-E1 Cells Induced by Serum Deprivation through cAMP/PKA/β-Catenin and PI3K/AKT/GSK3β Signaling Pathways.
IRS-1 increases TAZ expression and promotes osteogenic differentiation in rat bone marrow mesenchymal stem cells
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin
Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients
SIRT1 and insulin resistance
Comparison of the Spine and Hip BMD Assessments Derived from Quantitative Computed Tomography
Associations between fat distribution and volumetric bone mineral density in Chinese adults
IGF1 promotes osteogenic differentiation of mesenchymal stem cells derived from rat bone marrow by increasing TAZ expression
Effects of Growth Hormone Replacement Therapy on Bone Mineral Density in Growth Hormone Deficient Adults: A Meta-Analysis
Impaired PI3 K Akt expression in liver and skeletal muscle of ovariectomized rats
The association between metabolic syndrome and bone mineral density: a meta-analysis